139 related articles for article (PubMed ID: 37985171)
21. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.
Lagneaux L; Delforge A; Dorval C; Bron D; Stryckmans P
Blood; 1993 Oct; 82(8):2379-85. PubMed ID: 7691258
[TBL] [Abstract][Full Text] [Related]
22. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
23. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.
Van Damme M; Crompot E; Meuleman N; Maerevoet M; Mineur P; Bron D; Lagneaux L; Stamatopoulos B
Clin Epigenetics; 2016; 8():132. PubMed ID: 27980696
[TBL] [Abstract][Full Text] [Related]
24. Haemophagocytic lymphohistiocytosis as a consequence of untreated B-cell chronic lymphocytic leukaemia.
Bailey C; Dearden C; Ardeshna K
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28446487
[TBL] [Abstract][Full Text] [Related]
25. Leukaemia cutis after starting bendamustine: cause or coincidence?
Mawri S; Nabi S; Jallad B; Won J
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26392439
[TBL] [Abstract][Full Text] [Related]
26. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
27. Hemophagocytosis in a patient with persistent chronic lymphocytic leukemia.
Kamangar E; Zhao W
Blood; 2013 Sep; 122(13):2149. PubMed ID: 24195125
[No Abstract] [Full Text] [Related]
28. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
[TBL] [Abstract][Full Text] [Related]
29. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
30. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
Sharman JP; Burke JM; Yimer HA; Boxer MA; Babu S; Li J; Mun Y; Danilov AV;
Leuk Lymphoma; 2021 Apr; 62(4):791-800. PubMed ID: 33243049
[TBL] [Abstract][Full Text] [Related]
31. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
[No Abstract] [Full Text] [Related]
33. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
36. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
37. GM-CSF treatment in patients with B-chronic lymphocytic leukemia.
de Nully Brown P; Hansen MM
Leuk Lymphoma; 1999 Jan; 32(3-4):365-8. PubMed ID: 10037035
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis.
Goel S; Polski JM; Imran H
Ann Clin Lab Sci; 2012; 42(1):21-5. PubMed ID: 22371906
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
